Related Experiment Video
Updated: Dec 25, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
516
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
Paul Cornes1, Pere Gascon2, Arnold G Vulto3,4
1Comparative Outcomes Group, Bristol, UK. paul.cornes@yahoo.co.uk.
Summary
Biosimilar pegfilgrastim offers improved patient adherence and cancer survival rates compared to under-dosed filgrastim. Its introduction can optimize neutropenia management and provide economic benefits.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Febrile neutropenia (FN) is a severe chemotherapy complication impacting cancer survival.
- Granulocyte colony-stimulating factor (G-CSF) reduces FN, with biosimilar options improving access and cost-effectiveness.
Purpose of the Study:
- To evaluate the impact of biosimilar pegfilgrastim on neutropenia management.
- To compare the effectiveness of biosimilar pegfilgrastim and filgrastim in clinical practice.
Main Methods:
- Review of clinical guidelines and real-world data on G-CSF use for FN prophylaxis.
- Comparison of efficacy between once-cycle pegfilgrastim and multi-day filgrastim administration.
Main Results:
- Biosimilar pegfilgrastim and filgrastim are equally effective when administered per guidelines.
- Filgrastim is often under-dosed in practice, leading to inferior outcomes compared to pegfilgrastim.
- Pegfilgrastim's once-cycle dosing may improve patient adherence.
Conclusions:
- Biosimilar pegfilgrastim presents an opportunity to enhance neutropenia management and cancer survival.
- Widespread adoption of biosimilar pegfilgrastim, supported by guidelines and multidisciplinary teams, is recommended for optimal benefits.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
179
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
179
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
381
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
381
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K